d-301

Benzoxonium chloride, The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (Thio-Ben) along with cryotherapy.

KD-3010 (Kalypsys) is an orally active potent and selective PPARδ agonist for the study of liver injury.

Compound 3013969, with CAS No. 247571-77-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 3013969 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

D3017, the primary alcohol metabolite of D2624, is orally active and possesses anticonvulsant properties. It has an ED50 value of 1.5 mg/kg in mice, and is applicable for studies on severe generalized tonic-clonic (grand mal) seizures and complex partial epilepsy.

KD-3010 is a peroxisome proliferator-activated receptor delta agonist potentially for the treatment of diabetes and obesity. KD-3010 dramatically ameliorates liver injury induced by carbon tetrachloride (CCl(4)) injections. Deposition of extracellular matrix proteins was lower in the KD3010-treated group than in the vehicle- or GW501516-treated group. Interestingly, profibrogenic connective tissue growth factor was induced significantly by GW501516, but not by KD-3010, following CCl(4) treatment.

Rislenemdaz (CERC-301) (CERC-301) is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B).

Indibulin (D 24851) is a synthetic small molecule with antimitotic and potential antineoplastic activities.Indibulin an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis.